// App-Quantinova.ai

P662 : PATIENT-REPORTED OUTCOMES FROM A PHASE 3 RANDOMIZED STUDY OF ZANUBRUTINIB VERSUS BENDAMUSTINE PLUS RITUXIMAB (BR) IN PATIENTS WITH TREATMENT-NAÏVE (TN) CLL/SLL

Researchers

Presenter

  • Paolo Ghia

Principal Investigators

  • Gisoo Barnes

  • Keri Yang

  • Constantine Tam

  • Peter Hillmen

  • Tadeusz Robak

  • Jennifer Brown

  • Brad Kahl

  • Tian Tian

  • Jason Paik

  • Mazyar Shadman

Medical Centers

  • St. James's University Hospital,Leeds,Reino Unido

  • Dana-Farber Cancer Institute Boston,Boston,Stati Uniti

  • Washin

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • Dana-Faber Cancer Institute,Boston,Verenigde Staten

  • Washington University School of Medicine, St. Louis, MO

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • BeiGene USA, Inc.,San Mateo,États-unis

  • Dana-Farber Cancer Institute Boston,Boston,Stati Uniti

  • Dana-Farber Cancer Institute, Boston, MA, United States

  • Dana-Faber Cancer Institute,Boston,Verenigde Staten

  • Peter MacCallum Cancer Centre,Melbourne,Австралия

  • Fred Hutchinson Cancer Research Center, Seattle, WA,Seattle, WA,Estados Unidos

  • Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy

  • St James's University Hospital,Leeds,Royaume-uni

  • Fred Hutchinson Cancer Research Center, Seattle, WA, United States

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • Dana-Farber Cancer Institute, Boston, MA

  • Medical University of Lodz, Lodz, Poland

  • BeiGene USA, Inc.,San Mateo, CA,Verenigde Staten

  • St. James's University Hospital,Leeds,Reino Unido

  • Medical University of Lodz,Lodz,Польша

  • BeiGene USA, Inc.,San Mateo, CA,Verenigde Staten

  • Fred Hutchinson Cancer Research Center, Seattle, WA,Seattle, WA,Estados Unidos

  • BeiGene USA, Inc., San Mateo, CA

  • St. James University Hospital,Leeds,Vereinigtes Königreich

  • StJamess University Hospital, Leeds, UK

  • BeiGene USA, Inc,San Mateo,United States

  • Medical University of Lodz, Lodz, Poland

  • Fred Hutchinson Cancer Research...

  • Fred Hutchinson Cancer Research Center, Seattle, WA, United States

  • Medical University of Lodz, Lodz, Poland

  • Fred Hutchinson Cancer Research Center, Seattle, WA, United States

  • Washington University in Saint Louis School of Medicine, Saint Louis, Missouri, United States

  • BeiGene USA, Inc.,San Mateo, CA,Stati Uniti

  • Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy

  • Medical University of Lodz, Lodz, Poland

  • Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy

  • Washington University School of Medicine, St. Louis, MO

  • Washington University School of Medicine,St. Louis, MO,Vereinigte Staaten

  • Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy

  • BeiGene USA, Inc.,San Mateo, CA,Estados Unidos

  • St. James's University Hospital, Leeds, United Kingdom

  • Washington University School of Medicine,St. Louis, MO,Vereinigte Staaten

  • Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • Fred Hutchinson Cancer Research Center, Seattle, WA,Seattle, WA,Estados Unidos

  • St. James University Hospital,Leeds,Vereinigtes Königreich

  • Dana-Farber Cancer Institute Boston,Boston,Stati Uniti

  • Washington University School of Medicine, St. Louis, MO

Locations

  • Italy

  • Algeria

  • Venezuela

  • United States

  • Australia

  • United Kingdom

  • Poland

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Bendamustine

  • Rituximab

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT03336333

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved